Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

1.605 -0.075 (-4.46%)
Streaming Delayed Price Updated: 2:40 PM EDT, Jun 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cognition Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Cognition Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan... 
Via Benzinga
News headline image
Cognition Therapeutics CEO Issues Letter to Shareholders
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
Gainers NKGen Biotech, Inc. (NASDAQ: NKGN) shares surged 60.9% to $6.08 in pre-market trading after gaining 8% on Thursday. NKGen Biotech presented Phase I clinical trial data at the 16th Annual... 
Via Benzinga
News headline image
Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Endeavor Group Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket ↗
Gainers Appreciate Holdings, Inc. (NASDAQ: SFR) shares surged 103.8% to $0.2460 in pre-market trading after falling around 19% on Wednesday. Appreciate Holdings received a notice from Nasdaq regarding... 
Via Benzinga
News headline image
Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Why Microsoft Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
Gainers ReShape Lifesciences Inc. (NASDAQ: RSLS) shares surged 62.8% to $0.3348 in pre-market trading after gaining over 6% on Tuesday. ReShape Lifesciences recently announced pricing of $3.0 million... 
Via Benzinga
News headline image
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Announces Participation in Upcoming September Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics – Could This Company's Technology Make Debilitating Neural Diseases Like Dementia A Thing Of The Past? ↗
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical stage neuroscience company developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic... 
Via Benzinga
News headline image
Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.